Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096338 · ClinicalTrials.gov registry record
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
A clinical trial of Prostate Cancer and Cardiovascular Diseases, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT05096338 is a study of Prostate Cancer and Cardiovascular Diseases that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 200 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05096338, a study of Prostate Cancer and Cardiovascular Diseases, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational study for patients with prostate cancer that will be treated with Androgen Deprivation Therapy. The study will help the investigators learn more about how these medications affect the heart and how those effects relate to patients' medical history and social determinants of health (such as race, gender identity, education, occupation, access to health services and economic resources). Patients on this study will have echocardiograms, blood draws, and answer questions about their symptoms and activity level. Patients will be followed on this study for up to 5 years.
Conditions Studied
Interventions
- OTHER Social Determinants of Health
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2029-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05096338
The ClinicalTrials.gov registry entry for NCT05096338 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Social Determinants of Health is the first listed.
NCT05096338 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05096338 about?
NCT05096338 is a clinical study titled "Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer". This is an observational study for patients with prostate cancer that will be treated with Androgen Deprivation Therapy. The study will help the investigators learn more about how these medications affect the heart and how those effects relate to patients' medical history and social determinants of ...
What is the current status of trial NCT05096338?
This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2021-10-27. Estimated completion is 2029-11.
What conditions does trial NCT05096338 study?
This clinical trial studies the following conditions: Prostate Cancer, Cardiovascular Diseases, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions.
What interventions are being tested in trial NCT05096338?
The interventions under investigation include: Social Determinants of Health (OTHER).
Who is sponsoring clinical trial NCT05096338?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05096338 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.